Subject: PDT
Unlocking precision medicine: An overview of Illumina's TSO500, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn about comprehensive genomic profiling (CGP) and the application of next-generation sequencing in oncology clinical trial biomarker studies. Attendees will gain insights into TruSight Oncology 500 (TSO500), a kitted GCP assay and research-use only tool that received the US Food and Drug Administration's (FDA) pre-market approval. The featured speakers will also cover the validation of TSO500 tissue and present preliminary data on circulating tumor DNA (ctDNA).
TORONTO, June 3, 2024 /PRNewswire-PRWeb/ -- ICON's experience with the TSO500 solid and liquid biopsy assay.
As next-generation sequencing (NGS) becomes a ubiquitous part of routine cancer care, its impact on designing and refining drug development remains in flux. Clinical trial design, biomarker identification and cohort analysis have begun to adapt to the changing landscape over the past decade; however, there are challenges with standardization and federation of data.
In this webinar, the speakers will explore the only kitted comprehensive genomic profiling (CGP) assay submitted to the US Food and Drug Administration (FDA) for pre-market approval (PMA) up to this point, TruSight Oncology 500 (TSO500). Available as a research-use-only tool, TSO500 sets the standard for reproducibility across sites, with exceptional accuracy and specificity across a broad range of preserved tissue types.
The expert speakers will also provide an overview of CGP, cover the validation of TSO500 tissue and present preliminary data on circulating tumor DNA (ctDNA). Moreover, the session will explore the application of NGS in oncology clinical trial biomarker studies, demonstrating its pivotal role in advancing personalized medicine in cancer treatment.
Register for this webinar today to gain insights on using NGS in biomarker studies and the impact of comprehensive genomic profiling on advancing personalized cancer treatment.
Join Jin Li, Senior Director, Scientific Affairs, ICON; and Jason Gottwals, Genomic Enablement Manager - AMR, Illumina, for the live webinar on Monday, June 17, 2024, at 10am EDT (3pm BST/UK).
For more information, or to register for this event, visit Unlocking precision medicine: An overview of Illumina's TSO500.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Soumya Shashikumar, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
SOURCE Xtalks
These press releases may also interest you
|
News published on and distributed by:
